Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,997,569
  • Shares Outstanding, K 93,900
  • Annual Sales, $ 1,243 M
  • Annual Income, $ -535,980 K
  • 60-Month Beta 0.94
  • Price/Sales 8.83
  • Price/Cash Flow N/A
  • Price/Book 12.59
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 63.66% ( +0.38%)
  • Historical Volatility 24.95%
  • IV Percentile 64%
  • IV Rank 13.07%
  • IV High 247.47% on 10/20/23
  • IV Low 36.02% on 12/01/23
  • Put/Call Vol Ratio 0.22
  • Today's Volume 3,372
  • Volume Avg (30-Day) 1,389
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 71,295
  • Open Int (30-Day) 74,299

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 7
  • High Estimate 0.13
  • Low Estimate -0.62
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +90.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
114.37 +8.64%
on 04/19/24
131.16 -5.27%
on 03/28/24
-3.29 (-2.58%)
since 03/22/24
3-Month
114.37 +8.64%
on 04/19/24
143.00 -13.11%
on 02/16/24
+4.03 (+3.35%)
since 01/24/24
52-Week
55.25 +124.89%
on 10/31/23
159.89 -22.29%
on 05/15/23
-2.43 (-1.92%)
since 04/24/23

Most Recent Stories

More News
2 Biotech Stocks to Buy Hand Over Fist in April

These drugmakers have made important moves over the past year.

AMGN : 273.01 (-0.19%)
SRPT : 124.25 (+6.09%)
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

The threat is still emerging, but it could be significant.

SRPT : 124.25 (+6.09%)
RGNX : 16.04 (+0.88%)
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

SRPT : 124.25 (+6.09%)
ENPH : 107.17 (-5.56%)
GOOG : 161.10 (+0.74%)
GOOGL : 159.13 (+0.55%)
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

The upcoming regulatory decision on its latest drug could be big.

SRPT : 124.25 (+6.09%)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.

SRPT : 124.25 (+6.09%)
Sarepta Therapeutics: Q4 Earnings Snapshot

Sarepta Therapeutics: Q4 Earnings Snapshot

SRPT : 124.25 (+6.09%)
Is It Too Late to Buy Sarepta Therapeutics Stock?

The company's hyperfocus on its core area could continue to be highly lucrative.

SRPT : 124.25 (+6.09%)
Why Sarepta Therapeutics Stock Is Soaring Today

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

JPM : 193.08 (+0.49%)
SRPT : 124.25 (+6.09%)
2 Magnificent Growth Stocks to Buy With $500

No need to break the bank to invest in promising stocks.

SRPT : 124.25 (+6.09%)
VEEV : 200.52 (-0.29%)
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?

Bad news for one player does not always equal good news for another.

SRPT : 124.25 (+6.09%)
PTCT : 25.21 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 135.10
2nd Resistance Point 130.12
1st Resistance Point 127.18
Last Price 124.25
1st Support Level 119.26
2nd Support Level 114.28
3rd Support Level 111.34

See More

52-Week High 159.89
Last Price 124.25
Fibonacci 61.8% 119.92
Fibonacci 50% 107.57
Fibonacci 38.2% 95.22
52-Week Low 55.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar